Pre-order Enquiry
Request Free Sample
Investigation Report on Chinese Pregabalin Market, 2020-2024
SKU ID : CRI-15115051 | Publishing Date : 23-Jan-2020 | No. of pages : 30
Request Sample
Request Customization
Check Discounts
Pregabalin is a new-generation drug for neuralgia treatment. In Jul. 2004, it was approved by the European Union to treat some epileptic seizures in adults. In Dec. 2004, it was approved by the U.S. Food and Drug Administration (FDA) to treat diabetic peripheral neuralgia and postherpetic neuralgia. In 2006, generalized anxiety disorder and social anxiety disorder became new indications of Pregabalin. In 2007, Pregabalin was approved by the FDA as the first drug to treat fibromyalgia syndrome. In 2012, Pregabalin was approved by the FDA to treat spinal cord injury (SCI)-related pains. In 2010, Lyrica was approved to enter China.
According to Report, the sales value of Lyrica increased by more than 450 times from about CNY 200,000 in 2010 to over 90.74 million in 2018. Due to Lyrica's success, many domestic manufacturers applied for Pregabalin production. Chongqing Succeway Pharmaceutical Co., Ltd.'s Pregabalin (trade name: Lairuike) was put in the market after obtaining the production license in 2013 and is gradually taking market share from Pfizer. By sales value, in 2018, Pfizer's Lyrica had a market share of approximately 77.13%, and the rest market share was captured by the products of Chongqing Succeway Pharmaceutical Co., Ltd. It is estimated that Pfizer's Lyrica will continue to dominate the Chinese market from 2020 to 2024 but its market share will decline because of the price competition of China-made Pregabalin.
According to Report,there is a continuous rise in the number of people suffering from indications for Pregabalin. For example, the number of epileptics in China has exceeded 10 million and increases by 500 thousand every year. Therefore, Pregabalin has a bright prospect in China.
Topics Covered:
Development environment of Chinese Pregabalin market
Governmental approval of Pregabalin in China
Prices of Pregabalin in China
Major Pregabalin manufacturers in China
Factors influencing the development of Chinese Pregabalin market
Prospects of Chinese Pregabalin market
According to Report, the sales value of Lyrica increased by more than 450 times from about CNY 200,000 in 2010 to over 90.74 million in 2018. Due to Lyrica's success, many domestic manufacturers applied for Pregabalin production. Chongqing Succeway Pharmaceutical Co., Ltd.'s Pregabalin (trade name: Lairuike) was put in the market after obtaining the production license in 2013 and is gradually taking market share from Pfizer. By sales value, in 2018, Pfizer's Lyrica had a market share of approximately 77.13%, and the rest market share was captured by the products of Chongqing Succeway Pharmaceutical Co., Ltd. It is estimated that Pfizer's Lyrica will continue to dominate the Chinese market from 2020 to 2024 but its market share will decline because of the price competition of China-made Pregabalin.
According to Report,there is a continuous rise in the number of people suffering from indications for Pregabalin. For example, the number of epileptics in China has exceeded 10 million and increases by 500 thousand every year. Therefore, Pregabalin has a bright prospect in China.
Topics Covered:
Development environment of Chinese Pregabalin market
Governmental approval of Pregabalin in China
Prices of Pregabalin in China
Major Pregabalin manufacturers in China
Factors influencing the development of Chinese Pregabalin market
Prospects of Chinese Pregabalin market
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
